Category: JCN Newswire

TOKYO, Japan, July 31, 2025 – (JCN Newswire via SeaPRwire.com) –Honda Motor Co., Ltd. today launched a teaser page on its company website to share information on the all-new Prelude, which is scheduled to go on sale in September 2025.The all-new Prelude is a specialty sports model which represents the unrelenting Honda sports mindset, carrying forward the “joy of driving” into the electrified era, while also pursuing environmental performance and everyday usability.All-New Prelude Teaser Page: https://www.honda.co.jp/PRELUDE/new/All-new PreludeOverview of all-new PreludeGrand Concept: “Unlimited Glide” — Endless driving pleasure & Extraordinary experience —Inspired by the image of gliders soaring freely and boundlessly through the open sky, Honda developed the all-new Prelude under the grand concept of “Unlimited Glide,” striving for a vehicle that evokes the uplifting sensation of gliding gracefully through the air and extraordinary experience that people do not have in their everyday lives.Like a glider…

Developing dual-use UAVs for civil and defense applicationsAutomating the transport of heavy cargo with MHI’s multi-purpose medium-sized UAVAccelerating the transport of medications using a VTOL (vertical take-off and landing) UAV capable of flying long distances at high speedTOKYO, July 31, 2025 – (JCN Newswire via SeaPRwire.com) – Mitsubishi Heavy Industries, Ltd. (MHI) participated in a practical training exercise held on July 17 at the Japan Ground Self-Defense Force (JGSDF) Asaka Garrison (Nerima-ku, Tokyo), aimed at improving response capabilities in the event of an earthquake centered on the Tokyo metropolitan area. The training was conducted by the JGSDF Eastern Army in cooperation with local governments, with MHI joining at the request of the Japan UAS Industrial Development Association (JUIDA). MHI conducted training to transport relief supplies to isolated disaster victims using its medium-sized multirotor uncrewed aerial vehicle (hereinafter “medium-sized UAV”) currently being developed by its Com…

– Data Showed LEQEMBI Slowed Clinical Decline by 1.75 Points on CDR-SB at Four Years Compared to the Natural History of Alzheimer’s Disease- 56% of Patients with Low Tau Continued to Demonstrate Improved Cognitive and Daily Living Function at Four YearsTOKYO and CAMBRIDGE, Mass., July 31, 2025 – (JCN Newswire via SeaPRwire.com) – Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”)and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher,“Biogen”) announced today that the latest findings demonstrating the benefits of continuous treatment with lecanemab-irmb (U.S. brand name: LEQEMBI®), an anti-amyloid beta (AB) protofibril* antibody for the treatment of early Alzheimer’s disease (AD), were presented at the Alzheimer’s Association International Conference(AAIC) 2025, held in Toronto, Canada, and virtually. Only lecanemab fights AD in two ways – targeting both amyloid plaque and protofibrils*, which can impact tau downstream.Four Years of Lecanemab Therapy…

TOKYO and CAMBRIDGE, Mass., July 31, 2025 – (JCN Newswire via SeaPRwire.com) – Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”)and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher,“Biogen”) announced today that results on investigational maintenance therapy with subcutaneous autoinjector (SCAI) of lecanemab-irmb (U.S. brand name: LEQEMBI®), an anti-amyloid beta (AB) protofibril* antibody for the treatment of early Alzheimer’s disease (AD), were presented at the Alzheimer’s Association International Conference(AAIC) 2025, held in Toronto, and virtually. Only lecanemab fights AD in two ways—targeting both protofibrils and plaque, which can impact tau accumulation downstream.Importance of Ongoing Treatment and SC Development ProgramDue to the reaccumulation of AD biomarkers and return to placebo rate of decline after therapy is stopped1, Eisai is investigating a new lecanemab SC maintenance treatment option following 18 months of IV therapy so pati…

Santa Clara, CA, July 29, 2025, (ACN Newswire via SeaPRwire.com) – Meshy.ai, the world’s leading AI-powered 3D content generation platform, has launched the Meshy 5 Preview, offering early access to the next generation of AI 3D model generator. Built on the strong foundation of Meshy 4, this preview version introduces smarter generation tools, enhanced image alignment, sharper geometry, and over 500 new animations—empowering creators to build faster, cleaner, and more creatively than ever before.Trusted by 3 Million Creators – The Platform of Choice for Game DevelopersWith over 30 million 3D assets generated and a community of more than 3 million creators, Meshy has become the go-to AI platform for game developers, VFX artists, and 3D content professionals worldwide. Recognized by Andreessen Horowitz (a16z) as the only 3D tool featured in its list of “Most Popular AI Tools Among Game Developers,” Meshy is redefining how digital worlds are built—with speed, accuracy, and creative control.What’s New in Meshy 5 …

TOYOTA CITY, July 30, 2025 – (JCN Newswire via SeaPRwire.com) – Toyota Motor Corporation announces its sales, production, and export results for June 2025 as well as the cumulative total from January to June 2025, including those for subsidiaries Daihatsu Motor Co., Ltd. and Hino Motors, Ltd.For more details, please see the link below (detailed data).Click here for detailed sales, production, and export results (“Detailed data (Excel)”)URL https://global.toyota/en/company/profile/production-sales-figures/202506.html  Copyright 2025 JCN Newswire via SeaPRwire.com.

TOKYO and CAMBRIDGE, Mass., July 31, 2025 – (JCN Newswire via SeaPRwire.com) – Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito,“Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A.Viehbacher, “Biogen”) announced today that the two-year real-world study in the U.S of lecanemab (generic name, product name: LEQEBMI®), an anti-AB protofibril* antibody, was presented at the Alzheimer’s Association International Conference (AAIC) 2025, held in Toronto, Canada and virtually. Only lecanemab fights AD in two ways– targeting both amyloid plaque and protofibrils*, which can impact tau downstream.Lecanemab received traditional approval in the U.S. in July 2023 for the treatment of early Alzheimer’s disease (AD). This retrospective study was conducted to investigate the actual state of real-world clinical treatment with lecanemabat 15 medical centers in the U.S., with a final report scheduled for late in the third quarter of Eisai’s fiscal year ending March 31…

TOKYO, July 30, 2025 – (JCN Newswire via SeaPRwire.com) – Sharp Corporation has reached an agreement with Mitsubishi Chemical Corporation (Headquarters: Chiyoda-ku, Tokyo; President: Manabu Tsukimoto), the National Institute of Information and Communications Technology (NICT) (Headquarters: Koganei City, Tokyo; President: Hideyuki Tokuda), and TECHLAB Co., Ltd. (Headquarters: Tama City, Tokyo; President: Hiroshi Hatakeyama) to collaboratively develop ultra-compact and lightweight LEO (Low Earth Orbit) satellite communication user terminals for mobility applications.Left: Ultra-Compact and Lightweight LEO Satellite Communication User Terminal;Right: An Image of the Terminal Installed in a VehicleLEO satellite communication enables high-quality, high-speed connectivity even in challenging environments such as mountainous regions, at sea, and on remote islands. Sharp began developing LEO satellite communication user terminals in 2023 (*2), applying design and communication technologies honed through smartphone d…

Mitsubishi Heavy Industries aims to integrate DCIM (Data Center Infrastructure Management) into its One-stop solutions portfolio to offer digital services to data centersThe combination delivers a comprehensive view of data center infrastructure, enabling enhanced visibility, elevated operational efficiency and optimized energy consumptionTOKYO, July 29, 2025 – (JCN Newswire via SeaPRwire.com) – Mitsubishi Heavy Industries, Ltd. (MHI) has concluded an agreement with Modius® Inc., a US based provider of innovative software solutions for managing critical facilities for the data center and telecommunications markets. Under this agreement, MHI will integrate Modius’s OpenData® DCIM technology with MHI’s power, cooling, and control technologies to deliver a unique, market leading solution for Data Center Energy Management (DCEM). This collaboration is an example of MHI Group’s partnering efforts, and MHI Group will continue to build strategic partnerships globally.Modius’s OpenData DCIM platform provides real-tim…

Osaka, Japan, July 29, 2025 – (JCN Newswire via SeaPRwire.com) – Osaka Prefecture has finalized the detailed program for the OSAKA JAPAN SDGs Forum to be held on Friday, September 5, 2025.Under the Osaka SDGs Vision (formulated in 2020), Osaka Prefecture has set the goal of becoming a leading “SDGs advanced city” that contributes to achieving the SDGs on a global scale as the host city of the Osaka-Kansai Expo. To achieve this, Osaka is working collectively to create new SDGs initiatives. As part of these efforts, the OSAKA JAPAN SDGs Forum will be held at the Expo Hall “Shine Hat” located within the Osaka-Kansai Expo venue. This forum, traditionally organized as the National SDGs Forum by various local governments, will now take place at the Expo venue under the theme “EXPO for SDGs.” Its aim is to share pioneering actions with domestic and international audiences and to encourage all participants to think together about the future beyond 2030, “SDGs + beyond.” The forum’s concept, “Connecting Everyone’s Wis…

TOKYO, July 29, 2025 – (JCN Newswire via SeaPRwire.com) – Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that its in-house discovered tyrosine kinase inhibitor, “LENVIMA®” (generic name: lenvatinib mesylate), in combination with the anti-PD-1 antibody, pembrolizumab, and transarterial chemoembolization (TACE) has been approved by the National Medical Products Administration (NMPA) of China for unresectable, non-metastatic hepatocellular carcinoma.This approval is based on interim analysis results from the pivotal Phase III LEAP-012 trial. The results of this trial were presented at the European Society for Medical Oncology (ESMO) Annual Congress 2024 held in September 20241 and published in The Lancet in January 2025.2 In this trial, LENVIMA in combination with pembrolizumab and TACE (the “combination therapy”) demonstrated a statistically significant and clinically meaningful improvement in one of the trial’s primary endpoints, progression-free survival (PFS), reducing the r…

Olympus to take a significant equity stake in Swan EndoSurgical with a combined initial investment of at least $65 million.Swan EndoSurgical to develop an innovative endoluminal robotic system for less invasive therapeutic treatments.The total combined funding could reach up to $458 million if pre-agreed milestones are met and the program reaches term.TOKYO, July 25, 2025 – (JCN Newswire via SeaPRwire.com) – Olympus Corporation (Olympus), a global MedTech company committed to making people’s lives healthier, safer, and more fulfilling, today announced the conclusion of an agreement with Revival Healthcare Capital (Revival) to drive advancements in endoluminal robotics. Olympus and Revival will co-found Swan EndoSurgical, a new company dedicated to developing a novel robotic system designed to revolutionize gastrointestinal (GI) patient care in the future.Logo of Swan EndoSurgicalEndoluminal robotics aims to empower more physicians to safely perform innovative techniques, enhancing patient access to treatment …

TOKYO, July 25, 2025 – (JCN Newswire via SeaPRwire.com) – Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that it has been included in the FTSE4Good Index Series for the 24th consecutive year since its initial inclusion in 2002. The FTSE4Good Index Series is a global index series for socially responsible investment.The FTSE4Good Index Series was developed by FTSE Russell to promote investment in companies that meet global standards for Environmental, Social and Governance (ESG). Eisai received particularly high scores in “Corporate Governance”, “Anti-Corruption”, “Tax Transparency”, “Labor Standards”, “Customer Responsibility”, and “Water Security”. As of the end of June 2025, 2,045 companies worldwide and 278 Japanese companies were included in the FTSE4Good Index Series.In addition to the MSCI Selection Indexes, another global ESG investment index, Eisai is also listed in the FTSE Blossom Japan Index, the FTSE Blossom Japan Sector Relative Index, the MSCI Nihonkabu ESG Selec…

Kawasaki and Nagoya, Japan, July 24, 2025 – (JCN Newswire via SeaPRwire.com) – Fujitsu Limited and Nagoya University, a member of the Tokai National Higher Education and Research System (THERS), have jointly developed a technology to encourage the use of new transportation services and eliminate transportation gaps. The “social acceptance model-based simulation (SAMSIM)” simulates how psychological factors influence residents’ willingness to use new transportation options and combined with AI-powered digital rehearsal technology, it allows for proactive evaluation of strategies to ensure successful service adoption.Ride-sharing and self-driving cars have emerged as ways to address transportation gaps as populations age and driver shortages persist. However, the ease with which these new services are accepted varies depending on various psychological factors such as perceived safety, trust, and usefulness. To promote usage of these services, it is necessary to accurately understand the psychological factors th…

TOKYO, Japan, July 24, 2025 – (JCN Newswire via SeaPRwire.com) – Honda Motor Co., Ltd. (Honda) today revealed some details of how it will support the World Athletics Championships Tokyo 25 (WCH Tokyo 25), which will be held from September 13 through 21, 2025. As an official global partner, Honda will contribute to the sustainability objectives of WCH Tokyo 25 and also by supporting athletes who strive to realize their dreams by pushing beyond their limits at this premier competition in the sport of track and field.The Honda theme for WCH Tokyo 25 is “Maximizing the excitement and inspiration from the athletes’ great performance, through the realization of an environmentally-responsible and safe event by providing a wide variety of mobility products equipped with innovative technologies.” Honda is planning to support the theme by providing its environmentally-responsible vehicles, including electric vehicles, to be used as the official vehicles of the WCH Tokyo 25.One such vehicle will be the Honda CR-V e:FCEV…

– Rationalization of domestic production technologies and strengthening of the system in Japan for manufacturing divertor outer vertical targets for ITER- Seeking to contribute to the ITER Project and provide components for the prototype reactor for fusion energy and startup machinesTOKYO, July 23, 2025 – (JCN Newswire via SeaPRwire.com) – Hitachi, Ltd. (TSE:6501, “Hitachi”) and the National Institutes for Quantum Science and Technology (“QST”) began developing a second prototype, a full-scale mockup of an outer vertical target*1 which is one of the most important components of a divertor in January 2022. Divertors are important pieces of components used in the ITER fusion*2 experimental reactor that is under construction in Southern France. With streamlining the production method through measures such as the introduction of an automatic welding system as detailed below, we completed the second prototype in March 2025. Furthermore, we today announce that a high-heat-load sample of an outer vertical target has…

Showcasing a prototype LEO satellite communication terminal (*1) enabling high-speed, high-capacity communication in areas with limited cellular coverageTOKYO, July 23, 2025 – (JCN Newswire via SeaPRwire.com) – Sharp Corporation (herein after “Sharp”) will exhibit at the 2nd SPEXA – International Space Business Expo, held at Tokyo Big Sight (Koto-ku, Tokyo) from Wednesday, July 30 to Friday, August 1. Sharp will showcase a LEO satellite communication terminal under development, leveraging its expertise in compact, lightweight design and communication technologies from smartphone development, along with supporting applications and field trial initiatives.Booth Image – Main Exhibits* LEO Satellite Communication Terminal (Reference Exhibit)Sharp will exhibit the terminal and introduce potential use cases such as real-time data transmission, location sharing, and remote control in areas with limited cellular connectivity, including maritime and mountainous regions. The terminal is also proposed as a solution for …

TOKYO, July 23, 2025 – (JCN Newswire via SeaPRwire.com) – Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and KYORIN Pharmaceutical Co., Ltd.(Headquarters: Chiyoda-ku, Tokyo, President and CEO: Yutaka Ogihara, “KYORIN”) announced today that Eisai (Thailand) Marketing Co., Ltd. (“Eisai Thailand”), a subsidiary of Eisai, has launched overactive bladder treatment Beova® Tablets (generic name vibegron) in Thailand.In 2021, Eisai acquired exclusive development and marketing rights from KYORIN for the agent in ASEAN member states Thailand, the Philippines, Malaysia, and Brunei. Eisai Thailand submitted an application for marketing authorization in Thailand in March 2023, and received approval in June 2024. This launch is the first within Eisai’s licensed region. In addition to the release in Thailand, approval has also been obtained in the Philippines and Malaysia, with preparations underway for market entry.Overactive bladder (OAB) is a urological condition with trouble in pooling urine in the bla…

TOKYO, July 22, 2025 – (JCN Newswire via SeaPRwire.com) – Mitsubishi Motors Corporation (hereafter, Mitsubishi Motors) announced the termination of its engine business operation at Shenyang Aerospace Mitsubishi Motors Engine Manufacturing Co., Ltd. (hereinafter, SAME) in China and has terminated the joint venture partnership.Established in August 1997, SAME began engine production in 1998 and has played a key role in China’s expanding automotive market by supplying engines not only to Mitsubishi-branded vehicle manufacturers, but also to numerous Chinese automakers. However, in response to the rapid transformation of China’s automotive industry, Mitsubishi Motors has reassessed its strategy in the region and has decided to terminate its participation in the joint venture.About Mitsubishi MotorsMitsubishi Motors Corporation (TSE:7211) — a member of the Alliance with Renault and Nissan — is a global automobile company based in Tokyo, Japan, which has about 28,000 employees and a global footprint with production…

Latest findings from Eisai’s robust Alzheimer’s disease (AD) pipeline include results from lecanemab longterm data, an immunoassay for measuring amyloid-B protofibrils in cerebrospinal fluid, and asubcutaneousl form of lecanemab for continued treatment of ADAD is a progressive, relentless disease caused by a continuous underlying neurotoxic process that begins before and continues after plaque depositionTOKYO, July 22, 2025 – (JCN Newswire via SeaPRwire.com) – Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that the company will present the latest findings from its robust Alzheimer’s disease (AD) pipeline and research, including our dual-acting, anti-amyloid beta (AB) protofibril antibody for the treatment of AD, lecanemab (generic name, U.S. brand name: LEQEMBI®), and anti-MTBR (microtubule binding region) tau antibody, etalanetug (E2814), at the Alzheimer’s Association International Conference (AAIC), being held in Toronto and virtually from July 27-31. Eisai will present 21…